4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Vigonvita Life Sciences Co., Ltd. (2630) operates in the Drug Manufacturers - General industry and is headquartered in Suzhou, China with about 315 employees. Its market capitalization is roughly HKD 20 billion. In the fiscal year ended 2025-12-31, 2630 reported HKD 102M in revenue and (HKD 356M) in net income.
Vigonvita Life Sciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Revenue | HKD 102M | — | — |
| Gross Profit | HKD 81M | — | — |
| Operating Income (EBIT) | (HKD 315M) | (HKD 194M) | HKD 11M |
| Net Income | (HKD 356M) | — | — |
HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 |
|---|---|
| Total Assets | HKD 1.3B |
| Total Liabilities | HKD 854M |
HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2630 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms